Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODE V Deputy Bull Will Step In "As Needed" For Novartis-Bound DeLap

Executive Summary

FDA Office of Drug Evaluation V Deputy Director Jonca Bull, MD, is serving as the office's acting director in areas where departing Director Robert DeLap, MD/PhD, has conflicts of interest.

You may also be interested in...



ODE II Director Is Pulmonary & Allergy Division Chief Meyer

Pulmonary & Allergy Drug Products Division Director Robert Meyer, MD, will become Office of Drug Evaluation II director effective June 16

ODE II Director Is Pulmonary & Allergy Division Chief Meyer

Pulmonary & Allergy Drug Products Division Director Robert Meyer, MD, will become Office of Drug Evaluation II director effective June 16

Femara First-Line Breast Cancer Label Includes Tamoxifen Superiority Claim

Novartis' Femara (letrozole) first-line breast cancer approval Jan. 10 is based on superiority over tamoxifen (AstraZeneca's Nolvadex and Barr's generic).

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel